What Clavamox Treats: Main Uses and Benefits

The primary therapeutic role of Clavamox is to provide therapeutic support for a range of bacterial infections in dogs and cats, offering assistance across various therapeutic contexts in clinical situations where common microbial resistance is a concern. This medication is relevant in clinical settings for susceptible skin and soft tissue infections, periodontal infections in dogs, and urinary tract infections in cats.

The medication is commonly applied to conditions presenting with symptoms related to inflammatory or irritative states, such as pyoderma, abscesses, and infected wounds. It is also used in managing bacterial infection in key internal domains like the urinary tract and during treatment for periodontal disease. It helps address symptom clusters that may appear suddenly or intensify over time, contributing to improved day-to-day comfort during periods of acute symptomatic episodes.

The use of this combination is an applicable option in situations requiring temporary assistance in symptom stabilization, particularly when managing infections caused by bacteria that present significant challenges in management. This application supports general well-being during symptomatic phases.

Quick Fact: Managing Inflammation and Discharge (Supports easing the overall symptom burden when symptoms create noticeable physiological strain.)

Regulatory References

1. U.S. Food and Drug Administration (FDA) approval information

The eligibility for Clavamox (Amoxicillin/Clavulanate Potassium) is strictly defined by regulatory authorities for use in specific animal populations. It is officially labeled and approved for use in dogs and cats only.

Contraindications and Restrictions

The drug is formally contraindicated in any animal with a history of an allergic reaction to:

• Penicillins: Since the drug contains Amoxicillin, a penicillin-class antibiotic.
• Cephalosporins: Due to the potential for cross-sensitivity between the beta-lactam antibiotic classes.

Specific Limitations

Official labeling notes a restriction concerning reproductive safety:

• Pregnant or Breeding Animals: The safety of use in these populations has not been determined, placing them in a use-not-established category.

Interactions with other medicines and products

The official regulatory profile for the Amoxicillin/Clavulanic Acid combination details specific interactions that alter drug exposure or produce pharmacodynamic effects. All documented patterns and restrictions are based solely on information found in government prescribing labels, and the medicine is strictly contraindicated in patients with a history of hepatic dysfunction associated with its use.

Exposure-Altering Interactions	Interacting Substance	Official Regulatory Effect
Probenecid	Significantly increases Amoxicillin plasma concentrations and prolongs its half-life by inhibiting renal tubular secretion. Concomitant administration is officially not recommended.
Methotrexate	May decrease the renal excretion of Methotrexate, which is associated with increased serum concentrations of Methotrexate and an enhanced potential for toxicity.

Pharmacodynamic and Class Interactions Co-administration with Oral Anticoagulants (such as Warfarin) may prolong the prothrombin time (INR), an effect which mandates monitoring of coagulation parameters. The use of Allopurinol is officially associated with an increased incidence of skin rash. Furthermore, the bactericidal action of Amoxicillin may be potentially lessened by co-administration with bacteriostatic antibiotics. A reduction in the efficacy of Oral Contraceptives has also been noted in regulatory warnings.

Timing and Population Notes For optimal absorption of the clavulanic acid component, the medicine must be administered at the start of a meal. Clearance of the active ingredients is substantially reduced in patients with renal impairment, which is a documented consideration for managing drug exposure.

Inhibition of Bacterial Cell Wall Synthesis

Amoxicillin, a beta-lactam antibiotic, targets essential bacterial enzymes called penicillin-binding proteins (PBPs), which are responsible for constructing the protective peptidoglycan layer of the cell wall. By binding to and irreversibly inhibiting these enzymes, amoxicillin prevents the transpeptidation process necessary for the bacterial structural defenses. This action compromises cell wall integrity, resulting in subsequent bacterial lysis.

---

Overcoming Bacterial Enzyme Hydrolysis

Clavulanic acid, a beta-lactamase inhibitor, acts by binding to and irreversibly deactivating the beta-lactamase enzymes produced by bacteria. These enzymes typically hydrolyze and inactivate amoxicillin. This protective action ensures amoxicillin remains intact and active, enabling it to successfully inhibit the bacterial cell wall synthesis pathway, including in the presence of beta-lactamase enzymes.

How Clavamox is Used: Official Administration Guidelines

Clavamox (Amoxicillin/Clavulanate Potassium) administration is strictly defined by standardized dosing and delivery methods for dogs and cats. The medicine is available in various strengths of Chewable Tablets (e.g., 62.5 mg to 375 mg total combined drug) and as an Oral Suspension (Drops), with the sole route of administration being oral.

---

Official Dosing and Frequency

Usage follows a defined schedule, with the drug typically administered twice daily (approximately every 12 hours) for all approved indications.

Target Species	Standard Dosing Regimen (Total Combined Drug)
Dogs	6.25 mg per pound (lb) of body weight
Cats	A fixed total dose of 62.5 mg

---

Administration Requirements and Course Duration

Duration of use is dependent upon the type of infection being addressed. For routine skin and soft tissue infections, the course may last 5 to 7 days, continuing for up to 48 hours after all symptoms have subsided. More complex conditions, such as deep pyoderma in dogs, may necessitate treatment for up to 21 days, though the overall duration must not exceed 30 days.

Certain preparations require specific handling. The Oral Suspension must be reconstituted by adding a specified amount of water, and the resulting liquid must be refrigerated and discarded after 10 days. Chewable tablets are intended to be chewed completely before swallowing.

If a dose is missed, it should be given as soon as remembered. However, if it is close to the time of the next scheduled dose, the missed dose is skipped to resume the regular schedule, and double-dosing is prohibited.

---

Procedural Restriction

Therapy should be discontinued and the case re-evaluated if no clinical response is observed after 5 days of treatment in dogs or 3 days of treatment in cats.

Research evidence / Overview of studies for Clavamox

This overview describes the scope of research conducted on the Amoxicillin/Clavulanic Acid combination, focusing on what types of studies exist, what researchers monitored, and what aspects of the evidence remain uncertain, based only on regulatory and peer-reviewed scientific summaries.

---

Evidence for use in Skin and Soft Tissue Infections (Dogs and Cats)

Research examined Clavamox for conditions characterized by inflammation and acute changes, such as pyoderma, cellulitis, and infected wounds in both dogs and cats. The evidence base includes randomized, blinded clinical field studies that compared the combination product against the single-agent amoxicillin component. Findings describe patterns observed in the studies related to bacteriological response—specifically the patterns related to the presence or absence of certain target organisms known to resist the single-agent penicillin. Studies report how signs evolved in the observed populations associated with these infections. Long-term effects are not fully established, and there is limited information for outcomes beyond the immediate short-term period following the acute episode.

---

Evidence for use in Urinary Tract Infections (Cats)

Research explored the use of the combination for urinary tract infections (cystitis) in cats. Key research included pharmacokinetic (PK) studies to measure drug levels in the serum and urine, along with microbial susceptibility analysis of pathogens like E. coli. Reported data describe patterns related to the observed concentrations of the drug in the urine. Research also describes that the drug's processing in the body was observed in some studies to be different in cats with underlying health issues, such as azotemic Chronic Kidney Disease (azCKD). Sample sizes in specialized pharmacological studies, particularly those involving cats with comorbidities, were modest.

---

Research Gaps and Areas of Uncertainty

One key limitation is that comparative evidence against alternative active compounds is limited for randomized, head-to-head trials. Data for certain groups remain insufficient, and antimicrobial resistance patterns are dynamic. Studies continue to monitor this area of research uncertainty, which affects the susceptibility profiles of target bacteria over time.

Key Studies & References CLAVAMOX® CHEWABLE (Amoxicillin and Clavulanate Potassium Tablets): Product Information and Freedom of Information Summary (NADA 055-099)

Common questions about Clavamox (FAQ)

Q: What is Clavamox used for?

A: Clavamox is the brand name for a combination prescription medication containing amoxicillin and clavulanate potassium. It is indicated for treating infections caused by susceptible bacteria.

Q: How does Clavamox work?

A: The amoxicillin component is an antibiotic that helps prevent bacteria from building their cell walls. The clavulanate potassium component helps protect the amoxicillin from being broken down by certain enzymes produced by the bacteria, thereby helping the amoxicillin remain active.

Q: What are the potential side effects of Clavamox?

A: As with many medications, Clavamox may be associated with side effects. Common reported side effects include gastrointestinal upset, such as diarrhea, nausea, and vomiting. A healthcare provider can offer guidance on the full range of potential effects.

Storage and Disposal Requirements for Clavamox (Amoxicillin/Clavulanate)

The official storage conditions for Clavamox are determined by the drug's form, as defined in regulatory labeling.

Storage Requirements

Product Form	Required Conditions
Chewable Tablets/Dry Powder	Store in a cool, dry place at temperatures not above 25 C (77 F). Must remain in the foil strip until use.
Reconstituted Suspension	Must be stored under refrigeration (2 C–8 C / 36 F–46 F) and must not be frozen. Requires shaking before each use.

Stability and Disposal

The reconstituted liquid suspension has a strict 10-day stability period and must be discarded after this time, even if refrigerated. All Clavamox products must be stored out of reach of children and secured to prevent accidental ingestion by pets. Disposal of unused or expired medication should be conducted in accordance with local regulations.